• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Novozymes (CPSE:NSIS B) Expands In India, Is The Upside Already Priced In?

    Simply Wall St·09/03/2026 06:22:43
    Listen to the news

    Novozymes (CPSE:NSIS B) is back in focus after Novonesis announced a €600 million expansion of its Patalganga site in India, adding new enzyme production capacity across several end markets.

    For investors, these developments sit alongside a firm share price recovery, with a 30 day share price return of 10.37% and a 90 day share price return of 24.08%, helping lift the stock to DKK455.5. The 3 year total shareholder return of 57.40% points to momentum that has been building over a longer horizon.

    Extend your research beyond Novozymes and scan a curated 265 high quality undervalued stocks that share strong fundamentals and may be positioned for the next leg of momentum.

    The recent jump in Novozymes after the Novonesis expansion news forces a timing question. Is this the moment to pay up for the momentum, or does it make more sense to wait for a calmer entry before the numbers are crunched?

    Most Popular Narrative: 10% Overvalued

    With Novozymes last closing at DKK455.5 against a narrative fair value of DKK414, the current price bakes in expectations above that central estimate while still leaning on a relatively low discount rate of 5.71%.

    In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 30.7x on those 2029 earnings, down from 45.0x today. This future PE is greater than the current PE for the GB Chemicals industry at 19.0x.

    Read the complete narrative.

    Want to understand why Novozymes is being benchmarked against a future earnings level that requires a much richer multiple than many peers? The crux of this narrative is a blend of steady revenue compounding, firmer profit margins and a valuation that still leans on premium earnings quality. Curious which combination of growth and profitability assumptions needs to hold for that DKK414 fair value to make sense.

    Result: Fair Value of DKK414 (OVERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, there is still room for this Novozymes narrative to break either way if emerging market competition tightens or if bioenergy projects face policy or feedstock setbacks.

    Find out about the key risks to this Novozymes narrative.

    Another View on Novozymes Using Cash Flows

    The fair value of DKK414 reflects analyst earnings and P/E assumptions, yet the SWS DCF model points in a very different direction. On that approach, Novozymes is valued at DKK683.19 per share, which is above the current DKK455.5 price and flagged as undervalued. Which signal do you trust more?

    To see how this cash flow view is built and challenged, Look into how the SWS DCF model arrives at its fair value.

    NSIS B Discounted Cash Flow as at Sep 2026
    NSIS B Discounted Cash Flow as at Sep 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Novozymes for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 265 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    If this mix of optimism and caution around Novozymes feels familiar, use it as a prompt to move fast and test the numbers yourself. Then compare your own take on the upside drivers with the 3 key rewards

    Looking for more investment ideas beyond Novozymes?

    If you like the setup around Novozymes, do not stop there. Broaden your watchlist with other stocks that align with your style before the market moves first.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.